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Background:  We  assessed  the  risk  of  spontaneous  abortion  (SA)  after  inadvertent  exposure  to  HPV-16/18-
vaccine  during  pregnancy  using  an  observational  cohort  design.
Methods:  The  study  population  included  women  aged  15–25  years  registered  with  the  Clinical  Practice
Research  Datalink  General  Practice  OnLine  Database  in  the  United  Kingdom  (UK),  who  received  at  least
one HPV-16/18-vaccine  dose  between  1st September  2008  and  30th  June  2011.  Exposed  women  had  the
ﬁrst day  of  gestation  between  30  days  before  and  45  days  (90  days  for the  extended  exposure  period)  after
any HPV-16/18-vaccine  dose.  Non-exposed  women  had  the  ﬁrst day  of gestation  120 days–18  months
after  the last  dose.  SA  deﬁned  as  foetal  loss  between  weeks  1 and  23  of  gestation  (UK  deﬁnition).
Results:  The  frequency  of SA  was 11.6%  (among  207  exposed)  and  9.0%  (632  non-exposed),  women:
hazard  ratio (HR)  adjusted  for age  at  ﬁrst day of gestation  1.30  (95%  conﬁdence  interval:  0.79–2.12).
Sensitivity  analysis  per  number  of  doses  administered  (−30  to +45-day  risk  period)  showed  a  HR  for  SA
of  1.11  (0.64–1.91)  for  18/178  women  with  one  dose  during  the  risk  period  versus  2.55  (1.09–5.93) in
6/29  women  with  two  doses  within  a  4–5 weeks  period.  The  proportion  of  pre-term/full-term/postterm
deliveries,  small/large  for gestational  age  infants,  and  birth  defects  was  not  signiﬁcantly  different  between
exposed  and  non-exposed  women.  Results  were  consistent  using  a (United  States)  SA deﬁnition  of foetal
loss  between  weeks  1–19  and/or  the extended  risk  period.
Conclusion:  There  was  no  evidence  of an  increased  risk  of SA  and  other  adverse  pregnancy  outcomes
in  young  women  inadvertently  HPV-16/18-vaccinated  around  gestation.  Nevertheless,  women  who  are
pregnant  or  trying  to become  pregnant  are  advised  to postpone  vaccination  until  completion  of  preg-
nancy.
ublis© 2015  The  Authors.  P
. IntroductionCervarixTM (Human papillomavirus [HPV]-16/18-vaccine, GSK
accines) contains HPV-16 and HPV-18 virus-like particles
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formulated with the proprietary Adjuvant System, AS04. HPV-
16/18-vaccine is indicated for girls and women from 9 years of age
onwards, for the prevention of persistent infection, pre-cancerous
lesions, and cervical and other genital cancers caused by oncogenic
HPV.
Unintended exposure to HPV-16/18-vaccine prior to the onset
of pregnancy or during pregnancy is possible in the population
recommended for vaccination, and unplanned pregnancies and
their outcomes were closely monitored in clinical trials. A pooled
analysis of pre-licensure clinical trial data suggested a numeri-
cal imbalance in spontaneous abortion (SA) among young women
15–25 years of age when the ﬁrst day of the last menstrual period
 under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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oig. 1. Number of subjects identiﬁed as exposed or non-exposed according to time
DG  = ﬁrst day of gestation.
LMP) occurred between 30 days before and 45 days after (−30 to
45) any dose of HPV-16/18-vaccine (11.0%) versus controls who
eceived hepatitis A vaccine (5.8%) [1]. The Center for Biologics Eval-
ation and Research in the United States (US) requested that GSK
onduct a post-licensure analytic epidemiological study to investi-
ate these ﬁndings further [2].
An independent analysis of two studies of HPV-16/18-vaccine
oncluded that an increased SA risk among pregnancies conceived
ithin 3 months of vaccination could not be completely ruled out
3]. Post-licensure surveillance data indicate that pregnancy out-
omes including SA in pregnant women who were inadvertently
accinated with HPV-16/18-vaccine were in line with published
iterature in unvaccinated populations [4].
After a feasibility assessment (see web material), we assessed
he risk of SA within a cohort of vaccinated women and compare
regnancies exposed around gestation to a non-exposed cohort of
regnancies using the Clinical Practice Research Datalink General
ractice OnLine Database (CRPD GOLD) in the United Kingdom (UK).
he HPV immunisation programme between the 2008 and 2010
chool years, achieved a HPV-16/18-vaccine coverage of 89.0%,
7.6% and 83.8% for the ﬁrst, second and third doses, respectively,
y 2010/11 [5,6].
. Methods
.1. Data source, population and setting
CPRD GOLD is one of the largest anonymised primary care
atabase, and captures longitudinal medical records including
emographic and lifestyle parameters, clinical events, referrals to
pecialists and immunisation records from around 600 general
ractices [7]. Complementary information can be obtained through
he free text data practice management system from CPRD GOLD
7]. Additionally, a mother–baby link allows linkage of medical
ecords of women to those of offspring [8].
The study population included women aged 15–25 years regis-
ered in CPRD GOLD and with the ﬁrst day of gestation available
rom the database between 1st September 2008 and 30th June
011. Eligible women were to have received at least one dose
f HPV-16/18-vaccine during the same period (see web material
or CPRD GOLD HPV vaccination codes). Vaccinated women  who
eceived an unspeciﬁed HPV vaccine or Gardasil® (Merck & Co.)
ere excluded. Women  in the non-exposed cohort who had a previ-
us pregnancy included in the exposed cohort were also excluded. ﬁrst day of gestation in relation to HPV-16/18 vaccination.
If multiple pregnancy episodes occurred during the study period,
only the ﬁrst pregnancy in the database was considered for the
analysis.
The study protocol was  approved by the Independent Scientiﬁc
Advisory Committee for the Medicines and Healthcare Products
Regulatory Agency database research [9]. No patient informed con-
sent was  needed because patient information in CPRD GOLD is
fully anonymised. The study is registered at www.clinicaltrials.gov
NCT01905462, EU PAS Register Number ENCEPP/SDPP/3310.
2.2. Study cohorts
Exposed and non-exposed cohorts were deﬁned according to
the ﬁrst day of gestation, deﬁned as the ﬁrst day of LMP, or as the
estimated date of delivery minus 280 days (equal to the median
gestational age of 40 weeks), or as adjusted according to ultra-
sound dating, and exposure to HPV-16/18-vaccine as recorded in
CPRD GOLD. Exposed women  were those with ﬁrst day of gesta-
tion between −30 and +45 days after any HPV-16/18-vaccine dose
(an extended risk period −30 to +90 days after any HPV-16/18-
vaccine dose was  also considered) (Fig. 1). Non-exposed women
were protocol-deﬁned as having ﬁrst day of gestation between 120
days to 18 months after the last HPV-16/18-vaccine dose, and had
no further HPV-16/18-vaccine dose before the outcome (Fig. 1).
The analysis of SA excluded women  who were not pregnant,
or for whom the ﬁrst day of gestation was outside the study
period or not conﬁrmed after medical record review. The analysis
of other pregnancy outcomes, neonatal outcomes, and birth defects
excluded women  for whom the ﬁrst day of gestation was  not com-
patible with the conﬁrmed outcome, or women whose pregnancy
outcome was unknown.
2.3. Outcome deﬁnition
The primary study outcome was the occurrence of SA dur-
ing weeks 1–23 of gestation (UK deﬁnition). Secondary outcomes
included the occurrence of SA during weeks 1–19 of gestation
(US deﬁnition) and the occurrence of other pregnancy outcomes:
induced/therapeutic and other abortions, stillbirth (deﬁned as
intra-uterine death of foetus after 23 weeks gestation in the UK
or after 19 weeks gestation in the US), birth defects, small (deﬁned
as ≤10th percentile for sex and age on birth weight or length) or
large (≥90th percentile of normal weight or length) for gestational
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ge at birth [10], pre/post-term delivery and infant death before
ge 12 weeks.
.4. Data collection and case ascertainment
The ﬁnal study database consisted of data extracted from CPRD
OLD (Supplementary Fig. 1). Pregnancy outcomes were identi-
ed using pre-deﬁned algorithms (Supplementary Tables 1 and
). Information extracted included demographic characteristics,
bstetric history, lifestyle during pregnancy (smoking, alcohol con-
umption), medical conditions, vaccination records, and drug use
uring gestation. Speciﬁc de-identiﬁed free text associated with
regnancy endpoints, estimated date of delivery, ultrasound scan
ests and birth details was requested for pregnancy endpoint con-
rmation. All subject proﬁles were reviewed by Pallas, Health
esearch and Consultancy B.V., the Netherlands.
A safety physician within GSK reviewed all pregnancy outcomes
ther than live, full-term deliveries of normal weight-for-gestation
abies. Final case ascertainment was adjudicated by two  inde-
endent external experts specialised in teratology who  remained
linded with respect to the exposure status of the cases throughout
he ascertainment process. Final ascertainment of cases of SA with a
oubtful outcome, and all cases of therapeutic/other abortion, still-
irth, infant death and birth defect were reviewed by both experts.
ll other SA cases were reviewed by one expert, while the other
xpert reviewed a random sample of 10% of SA cases as a qual-
ty check (all decisions were in agreement with the classiﬁcation
ade by Pallas). One expert reviewed all cases of unrealistically
ong pregnancy (more than 43 weeks gestation).
.5. Statistical analysis
All statistical comparisons were made between the exposed
nd non-exposed cohorts. Demographic and baseline character-
stics were compared using Fisher’s exact test, Wilcoxon test or
ochran–Mantel–Haenszel test.
A Cox proportional hazards model that included the exposure
tatus as a binary independent variable and the age at ﬁrst day of
estation as a continuous covariate was used to estimate hazard
atios (HR) for SA. The dependent variable was the time between
he ﬁrst day of gestation and the event, or censoring (week 23 of
estation, date of induced/therapeutic abortion, date of maternal
eath, date of last available pregnancy data whichever occurred
rst). The aHR was derived as the exponential of the coefﬁcient
ssociated with the exposure status and its 95% Wald conﬁdence
nterval (95% CI) was estimated.
A planned sensitivity analysis used a Cox proportional hazards
odel, which in addition to age at ﬁrst day of gestation, included
he following covariates when they occurred in ≥5% of subjects:
moking, alcohol consumption, gestation start during the H1N1
andemic season, general practice region, diabetes and high blood
ressure during pregnancy, number of previous pregnancies, vac-
ination with another vaccine from −90 to +90 days gestation, and
se of contra-indicated drugs during the ﬁrst trimester of gesta-
ion. Another planned exploratory sensitivity analysis used Cox
roportional hazards models to assess the risk of SA according to
he number of doses received during the risk period (1 dose-, 2
ose-exposed subcohorts) compared to the non-exposed cohort.
dditional (post hoc) analyses assessed the number of doses and
ime of vaccination (before or after ﬁrst day of gestation); the dose
eceived (1st, 2nd, or 3rd dose) in the pre-deﬁned risk period; and
xcluding subjects receiving the third dose during the risk period.
We used criteria posed by the Vaccines and Medications in Preg-
ancy Surveillance System (VAMPSS, see supplement) to interpret
he results [11].(2015) 6884–6891
Logistic regression models were used to compare other preg-
nancy outcomes with occurrence of the outcome as a binary
dependent variable, the exposure status as a binary independent
variable and the age at ﬁrst day of gestation as a continuous covari-
ate. The odds ratio and its 95% CI were derived. It should be noted
that these adverse events were secondary endpoints and the study
was not powered to detect pre-deﬁned risks for these endpoints.
There was no previous safety signal for any other adverse preg-
nancy outcome.
2.6. Sample size
Based on a feasibility assessment which estimated the number
of potential eligible subjects and assuming a proportion of SA of
11.5% of pregnancies and that 20% of subjects would have incom-
plete 23-week gestation data, the study had 98% power to detect a
relative risk (HR) of 2.0 of SA between the exposed and non-exposed
cohorts subjects if the ﬁrst day of gestation was −30 to +45 days
after any dose of HPV-16/18-vaccine (two-sided log-rank test with
type I error rate of 5%). The HR detectable with 80% power was 1.69.
3. Results
Of 161,849 HPV-vaccinated women in CPRD GOLD, 1046 (0.6%)
met  the inclusion criteria (see web  material). Of  these, 839 (962
for the extended risk period) were included in the primary analysis
of SA: 207 (330) in the −30 to +45(+90) day exposed, and 632 in
the non-exposed cohorts (Supplementary Fig. 1). The non-exposed
cohort was approximately 6 months older than the exposed cohort
(p < 0.0001), around 3 months younger at ﬁrst vaccination dose
(p = 0.03), had fewer pregnancy onsets during the H1N1 pandemic
season (14.4% versus 36.2%, p < 0.001) and had fewer exposures to
other vaccines within 3 months before ﬁrst day of gestation (1.6%
versus 4.8%, p = 0.01) (Table 1). The cohorts were similar in terms
of general practice region, history of previous pregnancies and/or
SA. Information about lifestyle and medical history, when available,
indicated no differences between the cohorts (Table 1).
3.1. Pregnancy outcomes
3.1.1. Spontaneous abortion
Among 839 women  in the primary analysis (Fig. 1), pregnancy
outcome information was available in 87.0% (n = 730). SA occurred
in 9.7% (n = 81): 11.6% (n = 24) in the exposed cohort and 9.0%
(n = 57) in the non-exposed cohort. The mean gestational age at the
time of SA was  78.4 days (range 48–142 days) in the exposed cohort
and 73.7 days (range 34–134 days) in the non-exposed cohort.
The overall age-adjusted HR for SA in weeks 1–23 gestation in
women with ﬁrst day of gestation between −30 and +45 days after
any HPV-16/18-vaccine dose was  (1.30; 95% CI 0.79–2.12; p = 0.30)
(Table 2, Fig. 2).
The HR adjusted for other covariates was similar to the main
model (1.34, 95% CI: 0.81–2.24; p = 0.25). The model by number
of doses received during the risk period showed that for subjects
who received only 1 dose within the −45 to +30-day risk period
(n = 18/178), there was no increase in SA risk (aHR 1.11, 95% CI
0.64–1.91; p = 0.71). For women who received two doses of HPV-
16/18-vaccine within the −45 to +30-day risk period (n = 6/29), the
aHR was  2.55 (95% CI: 1.09–5.93, p = 0.03) (Table 2).
The ﬁndings for the extended −30 to +90-day risk period were
consistent with the main analysis (Supplementary Table 3). The
ﬁndings for the analysis deﬁning SA as occurring between weeks
1 and 19 gestation were also consistent with the main analysis for
both risk periods (Supplementary Table 4).
Additional analyses were conducted in order to explore the
observed increased risk of SA in women who had received two
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Table  1
Demographic characteristics of the exposed and non-exposed cohorts deﬁned according to the ﬁrst day of gestation (cohort for the analysis of spontaneous abortion, −30 to
+45  day and −30 to +90 day risk periods).
Characteristic Non-exposed,
N = 632
Exposed (−30 to
+45 days), N = 207
p-value Exposed (−30 to
+90 days), N = 330
p-value
n  (%) n (%) n (%)
Age in years at ﬁrst day of gestation Mean (SD) 18.5 (1.18) 17.9 (1.13) <0.0001 18.0 (1.18)) <0.0001
Range 15.2–23.9 15.1–23.3 – 15.0–23.3 –
9–15  year group 17 (2.7) 8 (3.9) <0.0001 13 (3.9) <0.0001
16–18 year group 386 (61.1) 174 (84.1) – 262 (79.4)
19–25 year group 229 (36.2) 25 (12.1) – 55 (16.7)
Age  in years at ﬁrst HPV-16/18 dose Mean (SD) 17.30 (1.14) 17.54 (1.10) 0.027 17.6 (1.12) <0.0001
Range 14.23–23.47 14.58–23.23 – 14.3–23.2
Region of residence North England 137 (21.7) 37 (17.9) 0.71 56 (17.0) 0.35
Midlands 96 (15.2) 33 (15.9) – 57 (17.3)
South England 259 (41.0) 90 (43.5) – 139 (42.1)
Ireland Scotland
Wales
140 (22.2) 47 (22.7) – 78 (23.6)
Marital status Single 105 (94.6) 37 (100) 0.01 55 (94.8) 0.02
Married–Engaged-
Co-habiting
6  (5.4) 0 (0.0) – 3 (5.2)
Missing 521 170 – 272
Number of previous pregnancies 0 164 (84.1) 78 (91.8) 0.33 116 (89.2) 0.46
1  22 (11.3) 5 (5.9) – 10 (7.7)
2  7 (3.6) 1 (1.2) – 2 (1.5)
3+  2 (1.0) 1 (1.2) – 2 (1.5)
Missing 437 122 – 200
Number of previous abortions/stillbirths 0 181 (85.0) 84 (92.3) 0.15 127 (90.1) 0.27
1  27 (12.7) 6 (6.6) – 11 (7.8)
2  3 (1.4) 0 (0.0) – 2 (1.4)
3+  2 (0.9) 1 (1.1) – 1 (0.7)
Missing 419 116 – 189
Smoking status during pregnancy Smoker 45 (11.2) 20 (14.0) 0.37 31 (14.3) 0.30
Missing 229 64 – 113
Alcohol consumption during pregnancy Yes 47 (29.0) 21 (32.3) 0.63 32 (30.5) 0.89
Missing 470 142 – 225
Diabetes during pregnancy Yes/probablea 8 (15.4) 2 (10.0) 0.72 5 (17.2) 1.0
Missing 580 187 – 301
High  blood pressure during pregnancy Yes 37 (8.0) 15 (9.3) 0.62 21 (8.3) 0.89
Missing 170 46 – 78
First  day of gestation during H1N1 pandemic Before 3 (0.5) 50 (24.2) <0.0001 65 (19.7) <0.0001
During 91 (14.4) 75 (36.2) 132 (40.0)
After 538 (85.1) 82 (39.6) 133 (40.3)
Number of HPV-16/18-vaccine doses 1 83 (13.1) 32 (15.5) 0.14 49 (14.8) 0.07
2  130 (20.6) 50 (24.2) – 86 (26.1)
3  417 (66.0) 125 (60.4) – 194 (58.8)
4  2 (0.3) 0 (0.0) – 1 (0.3)
Exposure to other vaccines <3 mo  before ﬁrst
day of gestation
10 (1.6) 10 (4.8) 0.015 24 (7.3) <0.0001
Exposure to contraindicated drugs Yes 215 (34.0) 74 (35.7) 0.67 119 (36.1) 0.57
N = number of subjects. p-value: Fisher exact test or Wilcoxon test, p-value for previous pregnancies, previous abortions and number of HPV vaccine doses are computed by
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dochran–Mantel–Haenszel. n/% = number/percentage of subjects in a given category
a Diabetes in the Exposed and non-exposed −30 to +45 cohort: yes = 7 cases and 
ases  and probable = 3 cases
oses of HPV-16/18 vaccine during the risk period. In women who
eceived one HPV-16/18-vaccine dose during the −30 to +45-day
isk period (n = 178), the Cox hazards proportional model did not
how evidence of increased SA risk, regardless of dose number (ﬁrst,
econd or third) or timing (before or after the ﬁrst day of gestation)
Table 2 and Fig. 2).
For women who received two doses during the risk period
n = 29), the numbers were too small to explore different timings
f exposure; for most women in whom one dose was administered
efore and one dose after the ﬁrst day of gestation (n = 23 aHR 2.80,
5% CI: 1.11, 7.06; p = 0.03).
Considering the extended −30 to +90-day risk period, the high-
st frequency of SAs occurred when the time-interval between
oses was 4–5 weeks (10/39, 26%) compared to an interval of longer
han 5 weeks (1/20, 5%). The gestational age at SA was  similar
mong the different cohorts and in subjects exposed to one or two
oses within either risk period (data not shown).
Applying VAMPSS criteria, based on the HR and on the conﬁ-
ence intervals, the proposed interpretation of our study resultsss otherwise speciﬁed). SD = Standard deviation.
ble = 3 cases. Diabetes in the exposed and non-exposed −30 to +90 cohort: yes = 10
are: “no evidence of risk” for the −30 to +45-day risk period
and “evidence of relative safety” for the −30 to +90 risk period
(for both the 1–23 and 1–19-week SA deﬁnitions) (Fig. 2). The
difference between the two  risk periods is mainly due to the width
of the CI related to the number of subjects (207 versus 330) than
a difference in the HR estimates (1.3/1.2). The results in a few
women who received two doses during the risk period would be
classiﬁed as showing “a positive association” whereas the results
showed “evidence of relative safety” for one dose exposure (and
similar results for the extended period).
3.1.2. Other pregnancy outcomes
There were seven stillbirths (0.8%), 1.4% (n = 3 at mean gesta-
tional age 185.7 days, range 162–204) in the exposed and 0.6%
(n = 4, mean gestational age 180.3-days, range 162–190) in the
non-exposed cohort. The proportion of pre-term, full-term and
post-term deliveries appeared to be similar amongst the exposed
and non-exposed cohorts (Table 3).
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Table 2
Cox proportion hazard analysis of SA during the ﬁrst 23 weeks of gestation – age adjusted, and for other covariates (cohort for the analysis of spontaneous abortion, −30 to
+45  day risk period).
Category N n (%) Adjusted HR (95% CI) p-value
Primary analysis (age adjusted)
Total 839 81 (9.7) – –
Exposed 207 24 (11.6) 1.30 (0.79; 2.12) 0.30
Non-exposed 632 57 (9.0) 1.00 –
Age  at ﬁrst day of gestation (continuous) – – 1.00 (0.82; 1.20) 0.96
Sensitivity analyses (adjusted for age and number of doses within the risk period)
1  dose 178 18 (10.1) 1.11 (0.64; 1.91) 0.71
2  doses 29 6 (20.7) 2.55 (1.09; 5.93) 0.03
Non-exposed 632 57 (9.0) 1.00 –
Age  at ﬁrst day of gestation (continuous) – – 0.99 (0.82; 1.19) 0.91
Sensitivity analyses (adjusted for age and covariates)
Exposed 207 24 (11.6) 1.34 (0.81; 2.24) 0.25
Non-exposed 632 57 (9.0) 1.00 –
Alcohol consumption during pregnancy 68 10 (14.7) 1.79 (0.78; 4.09) 0.17
Smoking during pregnancy 65 4 (6.2) 0.55 (0.20; 1.53) 0.25
High  blood pressure during pregnancy 52 3 (5.8) 0.56 (0.18; 1.81) 0.33
Vaccination 3 months before or after ﬁrst day of gestation 67 6 (9.0) 0.84 (0.36; 1.95) 0.69
Exposure to H1N1 pandemic 166 15 (9.0) 0.88 (0.49; 1.58) 0.67
Contraindicated drugs during pregnancy 289 29 (10.0) 1.06 (0.61; 1.84) 0.85
Region
Midlands 129 13 (10.1) 0.83 (0.41; 1.70) 0.62
South England 349 32 (9.2) 0.83 (0.47; 1.46) 0.52
Ireland–Scotland–Wales 187 16 (8.6) 0.74 (0.38; 1.43) 0.37
North England 174 20 (11.5) 1.000
Age  at ﬁrst day of gestation (continuous) – – 0.98 (0.81; 1.19) 0.86
Post  hoc analyses (adjusted for age and covariates)
1  or 2 dose exposure according to ﬁrst day of gestation
1 dose before 102 10 (9.8) 1.09; (0.55; 2.15) 0.82
1  dose after 76 8 (10.5) 1.15; (0.54; 2.44) 0.71
2  doses before 6 1 (16.7) 1.78; (0.25; 12.87) 0.57
1  dose before and 1 after 23 5 (21.7) 2.80; (1.11; 7.06) 0.03
Non-exposed 632 57 (9.0) 1.00 –
Age  at ﬁrst day of gestation (continuous) – – 0.99 (0.82; 1.20) 0.95
Dose  number (one dose)
1st dose 52 5 (9.6) 1.10 (0.44; 2.80) 0.84
2nd  dose 41 4 (9.8) 1.10 (0.39; 3.08) 0.86
3rd  dose 85 9 (10.6) 1.14 (0.56; 2.32) 0.71
Non-exposed 632 57 (9.0) 1.00 –
Age  at ﬁrst day of gestation (continuous) – – 1.00 (0.82; 1.23) 0.97
Excluding women who  received dose 3 only in the risk period
1 dose 93 9 (9.7) 1.08 (0.52; 2.23) 0.83
2  doses 29 6 (20.7) 2.54 (1.09; 5.92) 0.03
Non-exposed 632 57 (9.0) 1.00 –
Age  at ﬁrst day of gestation (continuous) – – 0.99 (0.81; 1.20) 0.90
N = number of subjects in a given category. n/% = number of SAs. HR = hazard ratio with Wald 95% CI.
Table 3
Pregnancy outcomes in the exposed and non-exposed cohorts (cohort for the analysis of spontaneous abortion, −30 to +45 day and −30 to +90 day risk periods).
Outcome category Exposed (−0 to +45), N = 207 Exposed (−30 to +90), N = 330 Non-exposed, N = 632
n  (%) n (%) n (%)
Known conﬁrmed outcome 182 (87.9) 227 (83.9) 548 (86.7)
Spontaneous abortion 24 (11.6) 34 (10.3) 57 (9.0)
Induced abortion 21 (10.1) 33 (10.0) 66 (10.4)
Therapeutic abortion 0 (0.0) 1 (0.3) 1 (0.2)
Other  abortion 0 (0.0) 0 (0.0) 2 (0.3)
Stillbirth 3 (1.4) 3 (0.9) 4 (0.6)
Live  birthsa 134 (73.6) 206 (74.4) 418 (76.3)
Pre-term delivery 6 (2.9) 16 (4.8) 27 (4.3)
Full-term delivery 109 (52.7) 167 (50.6) 349 (55.2)
Post-term delivery 19 (9.2) 23 (7.0) 42 (6.6)
At  least one small for gestation 8 (6.0) 14 (6.8) 27 (6.5)
At  least one large for gestation 1 (0.7) 4 (1.9) 14 (3.3)
Normal baby 64 (47.8) 88 (42.7) 186 (44.5)
Unknown for small/large for gestation 61 (45.5) 100 (48.5) 191 (45.7)
Unknown outcome 25 (12.1) 53 (16.1) 84 (13.3)
N = number of mothers. n/% = number/percentage of subjects in a given category. −30 to +45 day risk period.
a A total of ﬁve twin pregnancies resulted in three (full-term live births, one pre-term delivery and one stillbirth and one live pre-term birth from the same pregnancy).
−30  to +90 day risk period: seven twin pregnancies among them one stillbirth and one pre-term live birth from the same pregnancy, four full-term pregnancies and two
pre-terms pregnancies.
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Fig. 2. Hazard ratios (HR) and spontaneous abortion (SA) rates for main, sensitivity and post-hoc analyses (-30/+45-day risk period) and interpreted using safety thresholds
proposed by the Vaccines and Medications in Pregnancy Surveillance System [11].
The  safety of any exposure cannot be considered absolute; estimates of safety reﬂect the degree of conﬁdence that is consistent with an observation of no increased risk
between  a given exposure and outcome. Grey circle: no evidence of increased risk of SA in the exposed cohort (HR not statistically signiﬁcant and 95% conﬁdence interval
[CI]  upper limit of HR ≤4); Olive circle: evidence of relative safety in terms of the risk of SA in the exposed cohort (HR not statistically signiﬁcant and 95% CI upper limit of
HR  ≤2); Red circle: statistically signiﬁcant increased risk of SA in the exposed cohort (for subjects receiving 2 doses during the risk period a positive association was deﬁned,
b ge cir
G re las
9
a
9
t
c
T
B
N
d
a
aut  this ﬁnding was  based on 29 subjects included in the sensitivity analysis); Oran
reen circle: non-exposed cohort; N = number; Bef = vaccine dose administered befo
5%  Wald CI.
There were 557 babies born during the study period (51.4% male
nd 48.6% female). One minute Apgar scores were ≥8 in 89.7% and
1.3% of babies in each respective cohort.
Birth defects were conﬁrmed in seven babies (5.9%, 7/136) from
he exposed and 21 babies (6.0%, 21/421) from the non-exposed
ohorts (Table 4). There were three neonatal deaths of which two
able 4
irth defects in the exposed and non-exposed cohorts (cohort for the analysis of other pr
Characteristics Categories Exposed (−30 to +45), N = 136 
n  (%) 
Birth defect No 112 (94.1) 
Yes  – conﬁrmed 7 (5.9) 
Yes  – unconﬁrmeda 0 
Missing 17 
Classiﬁcationb At least one major birth defect 4 (57.1) 
At  least one minor birth defect 3 (42.9) 
NA  0 
Missing 129 
 = total number of babies. n/% = number/percentage of babies in a given category.
a The two unconﬁrmed birth defects were not classiﬁed (one congenital abnormality-n
b Major birth defects included: in the −30 to +45 day exposed cohort – positional talipes,
ay  exposed cohort – hypospadias. In the non-exposed cohort – microcephaly, developm
tresia, dislocation and subluxation of the hip, cystic kidney disease, cleft palate, cataract
nd  dysgenesis, horseshoe kidney.cle: no statistically signiﬁcant increased risk, but the 95% upper limit of the HR ≥4;
t menstrual period; Aft = vaccine dose administered after FGD; error bars represent
were within 7 days of birth: one with an unspeciﬁed congenital
abnormality and one with a thromboembolic disorder. The third
death was  due to sudden infant death syndrome 73 days after birth.
There was  no evidence of a difference in the risk of other preg-
nancy outcomes between the exposed and unexposed populations
for both risk periods (Supplementary Tables 5 and 6).
egnancy outcomes −30 to +45 day and −30 to +90 day risk periods).
Exposed (−30 to +90), N = 210 Non-exposed, N = 421 Total, N = 557
n (%) n (%) n (%)
167 (94.9) 327 (93.4) 439 (93.6)
9 (5.1) 21 (6.0) 28 (6.0)
0 2 (0.6) 2 (0.4)
34 71 88
5 (55.6) 11 (52.4) 15 (53.6)
4 (44.4) 10 (47.6) 13 (46.4)
0 2 2
201 398 527
ot further speciﬁed and one undescended testicle).
 diaphragmatic hernia, Trisomy 21, tetralogy of Fallot. Additionally in the −30 to +90
ental hip dysplasia, bilateral positional talipes, diaphragmatic hernia, oesophageal
 and lens abnormalities, peri-membranous ventricular septal defect, renal agenesis
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. Discussion
We  observed an SA rate during weeks 1–23 of gestation in UK
omen 15–25 years of age of 11.6% in the exposed cohort (ﬁrst
ay of gestation within −30 to +45 days of HPV-16/18-vaccine
dministration) and 9.0% in the non-exposed cohort. We  found no
vidence of an increased risk of SA in women whose ﬁrst day of
estation was within −30 to +45 (or −30 to +90) days of HPV-16/18-
accine administration, and there was no evidence of increased risk
f any other adverse pregnancy outcome in exposed women. In a
ensitivity analysis, we observed an increased risk of SA (n = 6) in
he 29 women who received two HPV-16/18-vaccine doses in the
isk period. Post hoc investigations suggested that the risk of SA
ncreased in six women receiving two doses within a 4–5 weeks
nterval, where one dose was administered before and one dose
fter ﬁrst day of gestation. The post hoc analyses conﬁrmed no
isk increase in subjects exposed to a single dose (HR close to 1)
egardless of dose number or timing in relation to the ﬁrst day of
estation.
The SA rates we observed are in range with the SA rate esti-
ate from the feasibility assessment performed in CPRD GOLD on
omen aged between 11 and 50 years (11.6%), and with published
ates for this and wider age ranges from the UK and developed
ountries [12–15]. The results are also consistent with an indepen-
ent analysis on SA made by the National Cancer Institute in the
nited States [3], and with a later pooled analysis of HPV-16/18-
accine clinical trial data from 40 countries and including data from
0,476 pregnancies, in which the SA rate within the −30 to +45 day
isk period was 12.9% in HPV-16/18 vaccinees and 10.1% in women
ho received control vaccines [16].
An additional analysis was conducted on a previously reported
ooled clinical trial database [16], that included women  aged 15–25
ears (N = 9359 pregnancies) vaccinated with HPV-16/18-vaccine
r a control vaccine. In women with a single dose of HPV-16/18
dministered during the −30 to +45-day risk period (N = 326) the
isk ratio (RR) was 1.54 (95% CI 0.95–2.54); compared to women
xposed to a control vaccine during the same period (N = 338);
he RR for two-dose exposure (N = 71) was 1.21 (95% CI 0.27–7.33)
ersus controls (N = 38) (GSK unpublished data).
This targeted safety study to assess the risk of SA has been con-
ucted in a large population-based database that is likely to be
epresentative of the general population of young women  in the
K. The CPRD GOLD database has been used to undertake other
esearch on pregnancy [17–19]. The assessment of SA rates in our
tudy was feasible using a combination of data coded in the CPRD
OLD, including the mother–baby link [20], and information from
ree text. We were able to conﬁrm study endpoints and preg-
ancy outcomes in the majority of women and made attempts to
inimise case ascertainment bias by blinding experts during case
eview. By deﬁning the non-exposed cohort as vaccinated women
ith a distant history of conﬁrmed HPV-16/18 vaccination, we
vercame the potential limitation related to incomplete vaccina-
ion records, increasing the speciﬁcity of the control group since
t is unlikely that women would be vaccinated again after com-
leting the three-dose HPV-16/18-vaccine schedule. Nevertheless,
3.1% and 20.6% of women had one or two recorded doses only
Table 1). So the risk that they were exposed to an unrecorded dose
ould not be totally excluded. This approach also decreased the risk
f differing healthcare behaviours between exposed and unvacci-
ated subjects, but led, as anticipated, to differences in terms of
ge at ﬁrst day of gestation and exposure to the H1N1 pandemic
1st June 2009–28th February 2010 [21]). However, adjustment for
hese covariates and others corroborated the results of the main
nalysis. Sensitivity analyses adjusted for other possible risk fac-
ors, including missing data, yielded virtually the same results as
he main analysis, suggesting that missing demographic data had(2015) 6884–6891
no impact on the study results. Finally, early SA (before 9 weeks
GA) may  go unrecognised. These pregnancies were probably not
documented in CRPD GOLD because women  were not aware of
their pregnancy. As they were not included in the denominator,
the risk of underestimation of SA rate should be therefore limited.
In conclusion, this study indicates that the rate of SA in HPV-16/18-
vaccinated young women is consistent with rates reported in the
literature. The results show that in young women who  are inadver-
tently vaccinated around gestation, there is no overall increase in
SA or in other adverse pregnancy outcomes compared to women
with similar characteristics from the same population who were
not exposed. Nevertheless, women  who  are pregnant or trying to
become pregnant, are advised to postpone vaccination until com-
pletion of pregnancy.
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